Physician's Evaluation of Cyclosporine Ophthalmic Emulsion 0.05%

Study Identifier
MA-RES-08-002
CT.gov Identifier
NCT00827255
EudraCT Identifier
Not available
EUCTIS ID
Not available
For general inquiries, please contact

844-663-3742 or [email protected]

Study Complete

Study Details

Medical Condition
  • Dry Eye
    • Study Drug
  • Cyclosporine Ophthalmic Emulsion 0.05%
    • Phase
    N/A
    Sex
    Female & Male
    Age
    16+ years
    Inclusion and Exclusion Criteria
    Inclusion Criteria:
    * Adults \>16 years of age * Dry eye patients * Subject with history of less than 12 weeks of initial RESTASIS® treatment * Subject started second trial of RESTASIS® treatment prior to June 1, 2008 * First day of second trial of RESTASIS® started ≥ 4 weeks after the last day of previous RESTASIS® treatment
    Exclusion Criteria:
    * Patients with Contact Lens Intolerance * Patients with Ocular Rosacea

    Protocol Summary

    The objective of this retrospective chart review is to evaluate the patient characteristics, treatment variations and efficacy of a second trial of Cyclosporine Ophthalmic Emulsion 0.05% therapy in chronic dry eye patients who were initially treated with Cyclosporine Ophthalmic Emulsion 0.05% but discontinued use after less than 12 weeks of treatment.

    Study Locations

    Location
    Status
    Location
    Pittsburgh, Pennsylvania, United States
    Status
    Not applicable